Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-612 Booster Extension Study in Healthy Adults
NCT04967742Phase 1Completed
- Sponsor
- United Biomedical, Inc.
- Start
- Aug 2021
- Primary completion
- Aug 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of UB-612 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by United Biomedical, Inc. Primary endpoints: Geometric Mean Titer (GMT) of neutralizing antibody against SARS-CoV-2 at Day 85, Geometric Mean Fold Increase of neutralizing antibody against SARS-CoV-2 at Day 85 and 1 more. Started Aug 2021; status: completed.
02
Drugs
UB-612
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04967742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04967742.